JP6958858B2 - テラヘルツ波を用いた細胞評価用の媒質 - Google Patents
テラヘルツ波を用いた細胞評価用の媒質 Download PDFInfo
- Publication number
- JP6958858B2 JP6958858B2 JP2017183035A JP2017183035A JP6958858B2 JP 6958858 B2 JP6958858 B2 JP 6958858B2 JP 2017183035 A JP2017183035 A JP 2017183035A JP 2017183035 A JP2017183035 A JP 2017183035A JP 6958858 B2 JP6958858 B2 JP 6958858B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- medium
- cancer
- terahertz wave
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011156 evaluation Methods 0.000 title claims description 35
- 238000000034 method Methods 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 20
- 230000003993 interaction Effects 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 191
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000002609 medium Substances 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 15
- 230000003834 intracellular effect Effects 0.000 description 14
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 14
- 201000009030 Carcinoma Diseases 0.000 description 12
- 230000005540 biological transmission Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 206010039491 Sarcoma Diseases 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001210 attenuated total reflectance infrared spectroscopy Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000011057 Breast sarcoma Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000009739 Mesodermal Mixed Tumor Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010051949 Peritoneal sarcoma Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010051950 Pleural sarcoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005102 attenuated total reflection Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 201000009023 maxillary cancer Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- -1 perfluoro Chemical group 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 208000010485 smooth muscle tumor Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Materials By Optical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
1)無極性の液体を含んでなる、テラヘルツ波を用いた細胞評価用の媒質。
2)上記無極性の液体は、フルオロカーボン類及び鉱物油類からなる群より選択される少なくとも一種である、1)に記載の媒質。
3)上記無極性の液体は、パーフルオロカーボン類である、1)又は2)に記載の媒質。
4)上記1)〜3)の何れかに記載の媒質中にある細胞と相互作用する領域に、テラヘルツ波を伝達する工程を含む、細胞の評価方法。
5)さらに、上記細胞とテラヘルツ波との相互作用を検出する工程を含む、4)に記載の方法。
6)検出する上記工程で得た結果を、基準と比較する工程を含む、5)に記載の方法。
7)評価対象である上記細胞とは異なる細胞であって、上記媒質中にある細胞とテラヘルツ波との相互作用を検出した結果を、上記基準とする、6)に記載の方法。
本実施形態に係るテラヘルツ波を用いた細胞評価用の媒質は、無極性の液体を含んでなる。
本実施形態における細胞の評価方法は、上述の媒質中にある細胞と相互作用する領域に、テラヘルツ波を伝達する工程を含む。さらに、この細胞とテラヘルツ波との相互作用を検出する工程を含むことが好ましい。
参考文献:APPLIED PHYSICS LETTERS 102, 053702(2013)。参考文献:J Infrared Milli Terahz Waves (2014) 35: 493-502。実施例及び図3も参照のこと。
参考文献:T. Mitsunaka et al., IEEE J. Solid-State Circuits, vol. 51, no. 11, 2016。
上記〔2.細胞の評価方法〕の欄で説明した比較工程を行うことによって得られた結果は、医師による診断を行う際の診断資料の1つとして利用することができる。また、上記〔2.細胞の評価方法〕の欄で説明した比較工程を行うことによって、疾患を有している可能性ありという結果が得られた被験体については、必要に応じて医師による診断の結果を伴った上で、治療を行うことができる。ここで、治療の一例としては、医師、場合によっては医師以外の専門家が行う、化学療法、放射線治療、及び外科手術などを挙げることができる。
文献:K. Shiraga et al., J. Infrared Milli. Terahz. Waves, 35, 493, 2014の2. Principle及び3. Methodに記載されている方法に則り、まず、37℃において水(培養培地)及びHeLa細胞単層の0.2〜4.0THzにおける複素誘電率を実験的に導出した。次いで、この複素誘電率について、以下の理論式で最小二乗フィッティングを行った。なお、ωは角周波数であり、iは虚数単位である。
図3の左に示すように、測定プリズム(誘電率ε1)上に厚さdのコンフルエントな細胞単層が形成されており、さらにその上には液体培養培地などの媒質が存在する3成分系を考える。ここでプリズムにシリコン単結晶(ε1=11.77)を用い、入射角θ=51.6°でテラヘルツ波がプリズム-細胞界面で反射すると、細胞側に局在する非伝搬性のエバネッセント波の局在深さdpは1THzで20μm程度となり、これは細胞厚み(約7μm:HeLa細胞の場合)を上回るため、本測定法では細胞単層上部に位置する媒質による影響の寄与が避けられない。
フロリナート(FC-3283(3M社製))中における細胞の生存状態を確認するために、タイムラプス観察を行った。5.0×104cells/mLの胃がん細胞(MKN7:RCB0999)をibidi μ-dish 35mm, high (#81156)上に播種し、培養培地(D-MEM (High Glucose with L-Glutamine, Phenol Red and HEPES)(#048-30275)+10% FBS (#S1820-500))中で、37℃、5%CO2下で24時間培養した。次いで、培養培地をアスピレーターで吸引除去し、D-PBS(-) (Calcium Chloride free, Magnesium Chloride free)でWashし、2mLのフロリナートを添加した。このdishを37℃、5%CO2下に静置し、0、6、12、18、20、24時間後における細胞の画像を、光学顕微鏡(NIKON Biostation)を用いて取得した。
上記のフロリナートに加え、他の媒質として鉱物油及びレモゾールについても細胞の生存状態に及ぼす影響についての確認の試験を行った。細胞培養用35mm ibidiディッシュ(フロリナート試験時)又はガラスボトムディッシュ(鉱物油、レモゾール試験時)に1×105個のNHDF細胞又はMKN7細胞をDMEM+10%FBSに播種し、37℃、5%CO2下で培養した(鉱物油及びレモゾールはibidiディッシュ腐食性があるためガラスボトムディッシュを使用)。培養から48〜72時間後、培養培地を各種の媒質に置換し、その直後から5分間隔で25時間目までBiostationで細胞を観察して細胞死の有無を評価した。細胞死の評価項目として、(1)細胞膜破壊による細胞膨化又は細胞質の漏出、(2)核の破壊、(3)細胞質における流動性の消失、を指標とし、そのいずれか1つにでも当てはまる細胞を死細胞とみなした。
Claims (7)
- 液体を含んでなる、テラヘルツ波を用いた細胞評価用の媒質であって、
上記液体は、フルオロカーボン類である、媒質。 - 上記液体は、パーフルオロカーボン類である、請求項1に記載の媒質。
- 上記パーフルオロカーボン類は、C5〜18パーフルオロカーボン、及びパーフルオロ−N−アルキルモルホリンからなる群より選択される少なくとも一種である、請求項2に記載の媒質。
- 請求項1〜3の何れか一項に記載の媒質中にある細胞と相互作用する領域に、テラヘルツ波を伝達する工程を含む、細胞の評価方法。
- さらに、上記細胞とテラヘルツ波との相互作用を検出する工程を含む、請求項4に記載の方法。
- 検出する上記工程で得た結果を、基準と比較する工程を含む、請求項5に記載の方法。
- 評価対象である上記細胞とは異なる細胞であって、上記媒質中にある細胞とテラヘルツ波との相互作用を検出した結果を、上記基準とする、請求項6に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017183035A JP6958858B2 (ja) | 2017-09-22 | 2017-09-22 | テラヘルツ波を用いた細胞評価用の媒質 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017183035A JP6958858B2 (ja) | 2017-09-22 | 2017-09-22 | テラヘルツ波を用いた細胞評価用の媒質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019060609A JP2019060609A (ja) | 2019-04-18 |
JP6958858B2 true JP6958858B2 (ja) | 2021-11-02 |
Family
ID=66178477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017183035A Active JP6958858B2 (ja) | 2017-09-22 | 2017-09-22 | テラヘルツ波を用いた細胞評価用の媒質 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6958858B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110283714B (zh) * | 2019-07-01 | 2022-04-01 | 中国人民解放军陆军军医大学第一附属医院 | 基于太赫兹和微流控的循环肿瘤细胞检测分离装置 |
WO2021241723A1 (ja) * | 2020-05-29 | 2021-12-02 | 学校法人兵庫医科大学 | 微生物検査方法および微生物検査装置 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3641123B2 (ja) * | 1997-12-26 | 2005-04-20 | 帝人株式会社 | ウィルスまたは細胞の培養法 |
GB2422310B (en) * | 2004-12-02 | 2006-12-27 | Kaizen Matsumoto | Carcinogen solvents in reducing the carcinogen concentration of cells |
JP5723643B2 (ja) * | 2011-03-22 | 2015-05-27 | 浜松ホトニクス株式会社 | 全反射分光計測方法 |
US20150219571A1 (en) * | 2014-02-04 | 2015-08-06 | Joseph R. Damers | Apparatus and method for detecting impurity in non-polar materials |
JP2016145815A (ja) * | 2015-01-30 | 2016-08-12 | キヤノン株式会社 | 情報取得装置及び情報取得方法 |
JP6672603B2 (ja) * | 2015-03-27 | 2020-03-25 | 株式会社豊田中央研究所 | 物質と細胞との間の作用の評価方法 |
CN106483059B (zh) * | 2016-10-13 | 2019-03-19 | 中国人民解放军第三军医大学第一附属医院 | 用于单个或少量活细胞无标记检测的太赫兹流式细胞传感器及其检测方法 |
-
2017
- 2017-09-22 JP JP2017183035A patent/JP6958858B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019060609A (ja) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mazzocchi et al. | Pleural effusion aspirate for use in 3D lung cancer modeling and chemotherapy screening | |
Sciacchitano et al. | Galectin-3: one molecule for an alphabet of diseases, from A to Z | |
Deptuła et al. | Tissue rheology as a possible complementary procedure to advance histological diagnosis of colon cancer | |
Willingham et al. | The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors | |
Reid et al. | Terahertz time-domain spectroscopy of human blood | |
Maiolo et al. | Colorimetric nanoplasmonic assay to determine purity and titrate extracellular vesicles | |
Xu et al. | Collective dynamics of lysozyme in water: terahertz absorption spectroscopy and comparison with theory | |
Xi et al. | The application of cell‐based label‐free technology in drug discovery | |
Cherkasova et al. | Diagnosis of glioma molecular markers by terahertz technologies | |
Vardaki et al. | Tissue phantoms for biomedical applications in Raman spectroscopy: a review | |
Jeong et al. | Characterization of blood using terahertz waves | |
Giordano et al. | Different shades of L1CAM in the pathophysiology of cancer stem cells | |
Wu et al. | Real-time evaluation of live cancer cells by an in situ surface plasmon resonance and electrochemical study | |
Tossetta et al. | Role of CD93 in Health and Disease | |
JP6958858B2 (ja) | テラヘルツ波を用いた細胞評価用の媒質 | |
Sahu et al. | Spectroscopic techniques in medicine: The future of diagnostics | |
Li et al. | Integration of multitargeted polymer-based contrast agents with photoacoustic computed tomography: an imaging technique to visualize breast cancer intratumor heterogeneity | |
Betriu et al. | Syndecans and pancreatic ductal adenocarcinoma | |
Bouaoud et al. | Unmet needs and perspectives in oral cancer prevention | |
Dutta et al. | Real-time detection of circulating tumor cells in living animals using functionalized large gold nanorods | |
Kelp et al. | Application of metasurface-enhanced infra-red spectroscopy to distinguish between normal and cancerous cell types | |
Haka et al. | Noninvasive detection of inflammatory changes in white adipose tissue by label-free Raman spectroscopy | |
CN108780089A (zh) | 评估细胞间的蛋白质相互作用的方法 | |
Lu et al. | Intracellular heat transfer and thermal property revealed by kilohertz temperature imaging with a genetically encoded nanothermometer | |
Hamdy et al. | Optical characterization of biological tissues based on fluorescence, absorption, and scattering properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200618 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210914 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210929 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6958858 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |